Philadelphia Pharmaceuticals Company (ASE:PHIL)
Jordan · Delayed Price · Currency is JOD 2.000
+0.010 (0.50%)
At close: Jul 30, 2026
ASE:PHIL Ratios and Metrics
Market cap in millions JOD. Fiscal year is January - December.
Millions JOD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 15 | 12 | 11 | 11 | 10 | 10 | |
Market Cap Growth | 36.05% | 6.67% | 4.90% | 2.88% | 1.46% | -4.20% |
Enterprise Value | 16 | 12 | 12 | 11 | 11 | 11 |
Last Close Price | 2.00 | 1.53 | 1.37 | 1.24 | 1.16 | 1.09 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 14.15 | 11.94 | 13.69 | 13.29 | 14.87 | 25.05 |
PS Ratio | 1.67 | 1.31 | 1.28 | 1.28 | 1.24 | 1.56 |
PB Ratio | 1.11 | 0.89 | 0.86 | 0.84 | 0.84 | 0.85 |
P/TBV Ratio | 1.11 | 0.89 | 0.86 | 0.84 | 0.84 | 1.06 |
P/FCF Ratio | 16.97 | 10.36 | 7.37 | 10.37 | 5.37 | 3.49 |
P/OCF Ratio | 13.20 | 8.75 | 6.54 | 9.75 | 4.95 | 3.27 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.76 | 1.35 | 1.36 | 1.36 | 1.28 | 1.66 |
EV/EBITDA Ratio | 9.77 | 6.95 | 7.13 | 6.94 | 8.83 | 12.45 |
EV/EBIT Ratio | 10.38 | 8.04 | 8.53 | 8.45 | 9.79 | 15.22 |
EV/FCF Ratio | 17.87 | 10.68 | 7.80 | 11.07 | 5.54 | 3.72 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.20 | 0.13 | 0.15 | 0.12 | 0.15 | 0.12 |
Debt / EBITDA Ratio | 1.63 | 0.99 | 1.19 | 0.90 | 1.50 | 1.65 |
Debt / FCF Ratio | 2.98 | 1.52 | 1.30 | 1.44 | 0.94 | 0.49 |
Net Debt / Equity Ratio | 0.06 | 0.00 | 0.03 | 0.01 | 0.03 | -0.02 |
Net Debt / EBITDA Ratio | 0.49 | -0.04 | 0.20 | 0.06 | 0.27 | -0.24 |
Net Debt / FCF Ratio | 0.90 | -0.06 | 0.22 | 0.09 | 0.17 | -0.07 |
Asset Turnover | 0.51 | 0.54 | 0.54 | 0.53 | 0.55 | 0.44 |
Inventory Turnover | 2.31 | 2.24 | 2.45 | 2.66 | 2.93 | 1.83 |
Quick Ratio | 2.50 | 2.81 | 2.90 | 2.39 | 2.27 | 2.87 |
Current Ratio | 3.26 | 3.72 | 3.67 | 3.08 | 2.73 | 3.48 |
Return on Equity (ROE) | 7.98% | 7.57% | 6.37% | 6.42% | 5.72% | 3.48% |
Return on Assets (ROA) | 5.39% | 5.67% | 5.34% | 5.32% | 4.44% | 2.99% |
Return on Invested Capital (ROIC) | 9.34% | 9.06% | 8.42% | 8.38% | 7.22% | 5.10% |
Return on Capital Employed (ROCE) | 10.70% | 10.80% | 10.10% | 10.60% | 8.90% | 5.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.07% | 8.38% | 7.30% | 7.53% | 6.73% | 3.99% |
FCF Yield | 5.89% | 9.65% | 13.57% | 9.64% | 18.62% | 28.63% |
Dividend Yield | 3.50% | - | 5.12% | 5.63% | 5.19% | 5.51% |
Payout Ratio | 49.53% | 52.23% | 63.91% | 55.75% | 64.18% | - |
Total Shareholder Return | 3.50% | - | 5.12% | 5.63% | 5.19% | 5.51% |